Ultra-luxury cruise line Silversea welcomed His Serene Highness the Prince Albert II of Monaco, His Excellency Minister of State of the Principality, Serge Telle , His Excellency Archbishop of Monaco Barsi, Mr. Peter Greenberg ( CBS-TV Travel Editor, Master of Ceremony), Mr. Geoffrey Kent ( Abercrombie & Kent Founder), Mr. Gerald Lawless ( Chairman of WTCC), VIPs and other distinguished guests to Port Hercule in the heart of Monaco, for an intimate ceremony marking the christening of the latest addition to their fleet, Silver Muse.
The historic celebration, which was hosted by Silversea Chairman Manfredi Lefebvre d’Ovidio, and was honoured by the amazing performance of Sinfonietta Orchestra of Rome, as well as the renowned Violinist Charlie Siem, providing the ceremony with a very elegant and amazing atmosphere.
Silver Muse, the ninth ship in the Silversea fleet, caters to the most discerning passengers at sea, offering the highest expression of elegance and comfort, redefining the ultra-luxury cruising experience.
To view the multimedia release go to:
https://www.multivu.com/players/English/8063251-silversea-christens-new-flagship-silver-muse/
Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), announced today that its first doses of the Fluzone® (Influenza Vaccine) portfolio for the 2017-2018 influenza (“flu”) season have been released by the U.S. Food and Drug Administration (FDA). Sanofi Pasteur has begun distributing initial shipments, representing the first of nearly 70 million total doses of seasonal influenza vaccine manufactured by the company for this upcoming influenza season. Widespread shipment of Fluzone Quadrivalent, Fluzone High-Dose and Fluzone Intradermal Quadrivalent vaccine to health care provider offices, pharmacies and other immunizers will begin in early August to support fall immunization campaigns.
“As we enter the Swiftwater site’s 120th year, it reminds us of our innovation and growth as we came to understand the science of influenza and its impact on human health,” said David P. Greenberg, M.D., Associate Vice President and Regional Medical Head North America, Sanofi Pasteur. “Influenza can be especially severe for the most vulnerable populations, including the elderly, young children and those with compromised immune systems; however, it can also have a serious health impact on otherwise healthy individuals. Sanofi Pasteur is and always has been deeply committed to improving public health by continuously striving to develop new vaccines and on improving existing ones.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8081151-sanofi-pasteur-influenza-vaccine-first-shipment-2017/
